IPO for "Double Chin" Solver KYTHERA Biopharmaceuticals (KYTH) iPO Opens 16% Higher
Tweet Send to a Friend
Up)
The IPO for KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) opened for trading at $18.49 after pricing 4,400,000 shares at $16, the top end of the expected $14-$16 range.
J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Leerink Swann LLC is acting as lead co-manager and Lazard Capital Markets LLC is acting as co-manager.
KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. KYTHERA’s product candidate, ATX-101, is an injectable drug currently in Phase III clinical development for the reduction of submental fat, which commonly presents as a "double chin."
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Leerink Swann LLC is acting as lead co-manager and Lazard Capital Markets LLC is acting as co-manager.
KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. KYTHERA’s product candidate, ATX-101, is an injectable drug currently in Phase III clinical development for the reduction of submental fat, which commonly presents as a "double chin."
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Iroko Pharma (IRKO Files $145M IPO
- Gigamon (GIMO) IPO Opens 21% Higher
- Gigamon (GIMO) Takes a Breather
Create E-mail Alert Related Categories
IPOsRelated Entities
JPMorgan, Lazard
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
